Reverce: A randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

K. Shitara, T. Yamanaka, T. Denda, Y. Tsuji, K. Shinozaki, Y. Komatsu, Y. Kobayashi, J. Furuse, H. Okuda, M. Asayama, K. Akiyoshi, Y. Kagawa, T. Kato, E. Oki, T. Ando, Y. Hagiwara, Y. Ohashi, T. Yoshino

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Fingerprint Dive into the research topics of 'Reverce: A randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients'. Together they form a unique fingerprint.

Medicine & Life Sciences